



26 **ABSTRACT**

27 **Background:** The usage rates of mineralocorticoids (fludrocortisone) to treat hyponatremia and  
28 isotonic crystalloids (saline and balanced crystalloids) to maintain intravascular volume in  
29 patients with aneurysmal subarachnoid hemorrhage (aSAH) patients across the United States  
30 are unknown.

31 **Methods:** We surveyed National Institute of Neurologic Disorders and Stroke (NINDS)  
32 StrokeNet sites, which are mostly large, tertiary, academic centers, and analyzed subarachnoid  
33 hemorrhage encounters in the Premier Healthcare Database that is representative of all types of  
34 hospitals and captures about 20% of all acute inpatient care in the United States.

35 **Results:** Although mineralocorticoids are used by 70% of the NINDS StrokeNet sites in aSAH  
36 patients, it is used in less than 25% of the aSAH encounters in the Premier Database. Although  
37 saline is ubiquitously used, balanced crystalloids are increasingly used for fluid therapy in aSAH  
38 patients. Its use in the NINDS StrokeNet sites and the Premier Healthcare Database is 41% and  
39 45%, respectively.

40 **Conclusions:** The use of mineralocorticoids remains low, and balanced crystalloids are  
41 increasingly used as fluid therapy in aSAH patients. The effectiveness of mineralocorticoids and  
42 balanced crystalloids in improving outcomes for aSAH patients must be rigorously tested in  
43 randomized clinical trials.

44

## 45 INTRODUCTION

46 Inpatient and overall mortality of patients with aneurysmal subarachnoid hemorrhage  
47 (aSAH) are 20% (1-3) and 40%, respectively (4). The high mortality rate results from life-  
48 threatening neurological sequelae and non-neurological complications, like fatal volume loss  
49 from kidney-drive natriuresis (cerebral salt wasting) (5-7). Ensuing hyponatremia and polyuria  
50 can be exceptional in aSAH patients, requiring treatment of hyponatremia and intravenous fluids  
51 to maintain their intravascular volume (8-10).

52 The 2023 American Heart Association aSAH guidelines recommend that “the use of  
53 mineralocorticoids is reasonable to treat natriuresis and hyponatremia” (11). Specifically,  
54 fludrocortisone is established to reduce natriuresis, hyponatremia, and polyuria in aSAH  
55 patients (9). A meta-analysis of the studies shows that mineralocorticoid use lowers the rate of  
56 symptomatic vasospasm in aSAH patients (9).

57 Maintaining intravascular volume is critical in aSAH patients. There are several options  
58 for maintenance intravenous fluid therapy: hypotonic or isotonic crystalloid solutions or colloid  
59 solutions. The Neurointensive Care consensus and clinical practice guidelines for stroke  
60 (including aSAH) and traumatic brain injury *strongly* recommend using crystalloids and against  
61 using colloid fluids (12). Given the importance of tonicity to control cerebral edema, isotonic  
62 rather than hypotonic crystalloids are most commonly used for intravenous maintenance fluid  
63 therapy.

64 The usage rates of fludrocortisone and different isotonic crystalloids across the United  
65 States are unknown. Efforts to understand the impact of these interventions are better informed  
66 with this information. In this short communication, we report the usage rates of fludrocortisone  
67 and isotonic crystalloids (saline or balanced crystalloids) from a survey of the National Institute  
68 of Neurologic Disorders and Stroke (NINDS) StrokeNet sites (which are mostly large, tertiary,  
69 academic centers) and in the Premier Healthcare Database.

70

71 **METHODS**

72 **NINDS StrokeNet Site Survey**

73 We surveyed the NINDS StrokeNet sites in May 2023. Within the 27 regional  
74 coordinating centers, there are 441 clinical performing sites in the StrokeNet network. The  
75 survey was filled out by the PIs at 87 sites (19.7% response rate). The following questions were  
76 asked:

- 77 - In which type of intensive care unit (ICU) does an SAH patient typically get admitted at  
78 your site?
- 79 ○ Dedicated neuro ICU
  - 80 ○ Other ICU
- 81 - Is the critical care of patients with aneurysmal SAH managed by a "closed" team? (i.e.,  
82 only one team placing orders for critical care management, i.e., "closed ICU")
- 83 ○ Yes
  - 84 ○ No
- 85 - Are plasma electrolytes assessed daily in SAH patients admitted to ICU?
- 86 ○ Yes
  - 87 ○ No
- 88 - How does your site treat hyponatremia in aneurysmal SAH patients? Check all that  
89 apply.
- 90 ○ Mineralocorticoid (i.e., fludrocortisone or hydrocortisone)
  - 91 ○ Enteral salt supplementation
  - 92 ○ Hypertonic saline
  - 93 ○ Desmopressin (DDVAP)
  - 94 ○ Other (specify)

- 95 - Does your site have a protocol for treating hyponatremia that all providers follow?
- 96       o Yes, all providers follow our site-specific protocol for treating hyponatremia.
- 97       o No, there is likely provider-dependent variation.
- 98 - What crystalloid is used for intravenous fluid therapy in SAH patients at your site? Check
- 99 all that apply.
- 100       o Saline (0.9% NaCl)
- 101       o Balanced crystalloids (Plasma-Lyte or lactated Ringer's)
- 102       o Other (specify)

103

#### 104 **Premier Healthcare Database**

105       We analyzed the service-level, all-payer Premier® Healthcare Database (PINC AI™ /

106 Premier Inc., Charlotte, NC) of electronic health records and hospital billing data from 2010 to

107 2020. It is a population-based research database with information from over 900 United States

108 hospitals and health systems. It includes real-world data from at least 45 states in the United

109 States and the District of Columbia, and it is estimated to capture approximately 20% of all

110 acute inpatient care in the United States. It is arguably representative with respect to hospital

111 size, geographic region, location (urban/rural) as well as profit, governmental, and teaching

112 status. Among the data, it includes diagnoses and treatments, such as procedures and

113 medications. Thus, we retrieved inpatient encounters from the Premier Healthcare Database

114 using both the International Classification of Diseases (ICD) 9 and 10 diagnoses codes for

115 subarachnoid hemorrhage (430 and I60) and who also had one or more of the following billing

116 CPT codes for a procedure to treat subarachnoid hemorrhage (61624, 75894, or any code from

117 61680 to 61711). From these encounters, the total number of encounters with one or more

118 orders of fludrocortisone, saline (normal or 0.9%), and balanced crystalloids (Plasma-Lyte or

119 lactated Ringer's) was counted.

120

## 121 **RESULTS**

### 122 **NINDS StrokeNet Site Survey**

123 Three of the 87 NINDS StrokeNet sites that responded to the survey did not answer  
124 questions about ICU characteristics (Figure 1). Of the 84 responses, 75 indicated that aSAH  
125 patients at their sites were admitted to a dedicated neurological ICU. The ICU is “closed” in 52  
126 sites. In sites where it is “open”, the critical care and neurosurgery teams jointly manage the  
127 critical care needs of the patients. All but one site (N=83) that responded assess plasma  
128 electrolytes daily.

129 All 87 sites responded to the question of hyponatremia treatment. From the most to least  
130 common, treatments used for hyponatremia were hypertonic saline (N=77, 88.5%),  
131 mineralocorticoid (N=61, 70.1%), enteral salt supplementation (N=59, 67.8%), and DDVAP  
132 (N=20, 23%). Other treatments included fluid restriction (N=5, 5.7%) and urea (N=1). Sixty-three  
133 (72.4%) sites do not have a protocol to treat hyponatremia in aSAH patients.

134 For intravenous fluid therapy, 77 (88.5%) sites use saline, and 36 (41.4%) use balanced  
135 crystalloids. Forty-three (49.4%) sites only use saline, and 4 (4.6%) sites only use balanced  
136 crystalloids. One site reported using sodium acetate.

137

### 138 **U.S.-Wide Use of Fludrocortisone and Fluids**

139 A total of 20,699 encounters of procedurally treated subarachnoid hemorrhage were  
140 retrieved from the Premier Healthcare Database from 2010 to 2020 (Figure 2). The use of  
141 fludrocortisone during this time increased gradually but remained less than 25%. For  
142 intravenous therapy, saline was used in nearly 100% of the encounters. The use of balanced  
143 crystalloids increased from 2010 to 2020, reaching the highest use (45%) in 2020.

144

## 145 **DISCUSSION**

146           Despite the recommendation by the 2023 (and in the previous 2012) American Heart  
147 Association aSAH guidelines that “the use of mineralocorticoids is reasonable to treat  
148 natriuresis and hyponatremia”(11) with a randomized level of evidence (Level B – Randomized)  
149 and moderate strength of evidence (2a – moderate; Benefit >> Risk), the use of  
150 mineralocorticoids in aSAH among the surveyed NINDS StrokeNet sites, which are largely  
151 tertiary academic centers was 70%. Even more noteworthy is its use is less than 25% in real-  
152 world practice data from Premier Healthcare Database. In the latter analysis, we did not include  
153 hydrocortisone which has the second highest but non-significant mineralocorticoid activity  
154 (relative potency of 0.008) compared to fludrocortisone (relative potency of 1)(13), because it is  
155 also commonly used to treat other conditions and may not accurately capture our aim to  
156 understand its use with the intent to treat natriuresis or hyponatremia. However, even with its  
157 inclusion, the usage rate of mineralocorticoids in aSAH patients is relatively lower in real-world  
158 practice compared to tertiary academic centers. Recent publications (14) suggest that  
159 uncertainty regarding the benefits of fludrocortisone treatment on aSAH outcomes may be a  
160 reason behind its low usage rates.

161           The usage rates of treatments of hyponatremia by the NINDS StrokeNet sites contrast  
162 those reported in the survey of 32 neurosurgical units in the United Kingdom and Ireland (15). In  
163 the latter survey, treatments used for hyponatremia were enteral salt supplementation (N=24,  
164 75%), fluid restriction (N=18, 56.2%), hypertonic saline (N=17, 53.1%), and fludrocortisone  
165 (N=7, 21.9%). Collectively, data from the United States, United Kingdom, and Ireland sites not  
166 only demonstrate geographic variation in the treatment, but also commonly highlight the lack of  
167 a protocol in the sites to treat hyponatremia. Among the NINDS StrokeNet sites, only 24  
168 (27.6%) sites have a protocol. Similarly, only 9 (28.1%) of the surveyed sites in the United  
169 Kingdom and Ireland have a protocol.

170 Maintaining intravascular volume is critical in aSAH patients, and crystalloid solutions  
171 are recommended and most commonly used. However, the formulation which offers the best  
172 outcomes for aSAH patients is unknown. Saline (0.9% NaCl) is the most commonly used  
173 crystalloid. Several randomized controlled trials in general and specific ICU patients have shown  
174 that balanced crystalloids, which have electrolyte composition similar to plasma, offer better  
175 outcomes compared to saline (16, 17). In our analysis, we estimated the usage rates of two  
176 balanced crystalloids—Plasma-Lyte or lactated Ringer’s—which are most commonly used. A  
177 limitation of our data from the Premier Healthcare Database is the inability to assess which was  
178 the primary fluid used since we captured the “order” for the fluid, not the quantity. Furthermore,  
179 there are other formulations such as Normosol-R, Isolyte S, Ringer’s acetate, and Hartmann’s  
180 solution whose usage rates we did not capture (18). Therefore, the collective usage rate of  
181 balanced crystalloid is probably slightly higher than what we report. However, in the context of  
182 increasing comparative effectiveness trials of balanced crystalloids versus saline, our data from  
183 the Premier Healthcare Database are noteworthy for the increasing use of balanced crystalloids  
184 in aSAH patients. Given their increase in usage, it is critical to study the impact of these  
185 crystalloid formulations in aSAH patients because a considerable volume of crystalloids (>16  
186 liters during the ICU stay) is given to them to maintain euvolemia (8-10). The volume given in  
187 the randomized control trials pales in comparison. Meager evidence exists to inform crystalloid  
188 selection in aSAH patients; one small study shows worse outcomes in aSAH patients with the  
189 use of balanced crystalloids (8). Their increasing use in the United States is an important reason  
190 to study the impact of different formulations of crystalloids used for intravenous fluid therapy.

191

## 192 **CONCLUSIONS**

193 Despite recommendations by the American Heart/Stroke Association guidelines, the use of  
194 mineralocorticoids remains low, and balanced crystalloids are increasingly used as fluid therapy



195 in aSAH patients. If mineralocorticoids and balanced crystalloids improve outcomes of aSAH  
196 patients must be rigorously tested.

197 **REFERENCES**

- 198 1. Chan V, Lindsay P, McQuiggan J, et al. Declining Admission and Mortality Rates for  
199 Subarachnoid Hemorrhage in Canada Between 2004 and 2015. *Stroke* 2019;50:181-184.
- 200 2. Lee VH, Ouyang B, John S, et al. Risk stratification for the in-hospital mortality in  
201 subarachnoid hemorrhage: the HAIR score. *Neurocrit Care* 2014;21:14-19.
- 202 3. Stienen MN, Germans M, Burkhardt JK, et al. Predictors of In-Hospital Death After  
203 Aneurysmal Subarachnoid Hemorrhage: Analysis of a Nationwide Database (Swiss SOS [Swiss  
204 Study on Aneurysmal Subarachnoid Hemorrhage]). *Stroke* 2018;49:333-340.
- 205 4. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid  
206 haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol*  
207 2009;8:635-642.
- 208 5. Chen S, Li Q, Wu H, et al. The harmful effects of subarachnoid hemorrhage on extracerebral  
209 organs. *Biomed Res Int* 2014;2014:858496.
- 210 6. Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and  
211 why? *Crit Care* 2015;19:309.
- 212 7. Solenski NJ, Haley EC, Jr., Kassell NF, et al. Medical complications of aneurysmal  
213 subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants  
214 of the Multicenter Cooperative Aneurysm Study. *Crit Care Med* 1995;23:1007-1017.
- 215 8. Mistry AM, Magarik JA, Feldman MJ, et al. Saline versus Balanced Crystalloids for Adults  
216 with Aneurysmal Subarachnoid Hemorrhage: A Subgroup Analysis of the SMART Trial. *Stroke*  
217 *Vasc Interv Neurol* 2022;2.
- 218 9. Mistry AM, Mistry EA, Ganesh Kumar N, et al. Corticosteroids in the Management of  
219 Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis.  
220 *Cerebrovasc Dis* 2016;42:263-271.

- 221 10. Barlow B, Thompson Bastin ML, Shadler A, et al. Association of chloride-rich fluids and  
222 medication diluents on the incidence of hyperchloremia and clinical consequences in  
223 aneurysmal subarachnoid hemorrhage. *J Neurocrit Care* 2022;15:113-121.
- 224 11. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With  
225 Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart  
226 Association/American Stroke Association. *Stroke* 2023;54:e314-e370.
- 227 12. Oddo M, Poole D, Helbok R, et al. Fluid therapy in neurointensive care patients: ESICM  
228 consensus and clinical practice recommendations. *Intensive Care Med* 2018;44:449-463.
- 229 13. Schimmer BP, Funder JW. Adrenocorticotrophic Hormone, Adrenal Steroids, and the Adrenal  
230 Cortex. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. *Goodman & Gilman's: The*  
231 *Pharmacological Basis of Therapeutics*, 13e. New York, NY: McGraw-Hill Education, 2017.
- 232 14. Busl KM, Rabinstein AA. Prevention and Correction of Dysnatremia After Aneurysmal  
233 Subarachnoid Hemorrhage. *Neurocrit Care* 2023.
- 234 15. Tominey S, Baweja K, Woodfield J, et al. Investigation and management of serum sodium  
235 after subarachnoid haemorrhage (SaSH): a survey of practice in the United Kingdom and  
236 Republic of Ireland. *Br J Neurosurg* 2021:1-4.
- 237 16. Collins MG, Fahim MA, Pascoe EM, et al. Balanced crystalloid solution versus saline in  
238 deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised,  
239 controlled trial. *Lancet* 2023;402:105-117.
- 240 17. Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill  
241 Adults. *N Engl J Med* 2018;378:829-839.
- 242 18. Semler MW, Kellum JA. Balanced Crystalloid Solutions. *Am J Respir Crit Care Med*  
243 2019;199:952-960.
- 244

245 **FIGURE LEGENDS**

246

247 **Figure 1. Results of NINDS StrokeNet Sites' survey, assessing their intensive care unit**  
248 **characteristics, hyponatremia treatments used, and types of fluids used to maintain**  
249 **intravascular volume in aneurysmal subarachnoid hemorrhage patients.**

250

251

252 **Figure 2. Fludrocortisone and crystalloids usage rates in subarachnoid hemorrhage**  
253 **patients in the Premier Healthcare Database.** From 2010 to 2020, 20,699 subarachnoid  
254 hemorrhage encounters were retrieved across about 350 hospitals in the United States with a  
255 CPT code involved in treating the ruptured aneurysm. The number above the dot indicates the  
256 actual number of encounters.

Response    Unresponsive    No    Yes



